Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669372 | 0.81 | MARS1 (0.64) | SLC2A1MARS1 | |
| SCHEMBL5670149 | 0.80 | MARS1 (0.51) | SLC2A1MARS1 | |
| SCHEMBL5670155 | 0.80 | MARS1 (0.51) | MARS1 | |
| SCHEMBL5669207 | 0.80 | MARS1 (0.76) | MARS1 | |
| Hydrochloric Acid SCHEMBL7815056 | 0.80 | MARS1 (0.66) | MARS1 | |
| SCHEMBL5670968 | 0.80 | MARS1 (0.48) | MARS1 | |
| SCHEMBL7992432 | 0.78 | MARS1 (0.60) | MARS1 | |
| SCHEMBL7815298 | 0.76 | MARS1 (0.67) | MARS1 | |
| SCHEMBL5669849 | 0.76 | MARS1 (0.76) | MARS1 | |
| SCHEMBL178914 | 0.76 | MARS1 (1.00) | MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351688-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039017-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, PLAUR | SLC2A1 2427/4885MARS1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.